The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1385
March 5, 2012
View Complete Issue         Table of Contents 2019 
Issue 1385
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Edarbyclor: An ARB/Chlorthalidone Combination for Hypertension
March 5, 2012 (Issue: 1385)
The FDA has approved a fixed-dose combination of the angiotensin receptor blocker (ARB) azilsartan and the thiazide-like diuretic chlorthalidone as Edarbyclor (Takeda) for treatment of hypertension
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1385
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.